Renovaro Group is driven by a steadfast commitment to revolutionize healthcare.
WHAT WE DO
Renovaro Group is driven by a steadfast commitment to revolutionize healthcare.
Our primary goals encompass pioneering advancements in biotechnology to develop groundbreaking therapies and diagnostic tools.
We aim to address unmet medical needs in diverse areas such as oncology, neurology, infectious diseases, and rare genetic disorders.
ABOUT RENOVAROCUBE
RenovaroCube is working to transform cancer detection through its advanced AI/Machine Learning platform that harnesses the power of multi-omics analysis and differential molecular capabilities. With access to vast amounts of big data, RenovaroCube is at the forefront of leveraging data mining techniques. Our unique library of over 2600 biomarker panels offers the flexibility to create custom panels for the pharmaceutical industry.
We are rapidly working to expand our platform for as many cancers as we possibly can. Utilizing differential molecular diagnosis and multi-omic analysis, our platform aims to enhance accuracy in the detection of multiple cancers, with a view to identifying them before traditional methods may find them. Our state-of-the-art AI/ML platform supports precision oncology, offering significant capabilities in minimal residual disease and recurrence monitoring. Thus, supporting patients in readmission allows routine checks, via blood draw, to be carried out, assessed, and then acted upon.
.
10+
Years of experience
2600+
ProprietaryBiomarker Panels
13
Tumors Validated In-Silico
Why work with us?
Differential Molecular Diagnostics
Based on biomarkers, genetics, tumor sequencing, & liquid biopsies.
Fast Discovery Process
After lab results and raw data have been supplied, results can be produced swiftly.
Precision Diagnostics
With a high accuracy target of > 95% based on proprietary algorithm.
Explainable AI
Every prediction is traceable and interpretable to the exact biomarkers, panels and genes.
High Reliability
High specificity target (>99%) and sensitivity (>70%).
Reduce Costs
For drug discovery and validation, the process is accelerated saving (expensive) R&D costs.
ABOUT RENOVAROBIO
We are a biotechnology company focused on developing advanced allogeneic cell and gene therapies to enhance immune responses, aiming for long-term cancer remission and potential cures for serious diseases such as HIV and HBV. Our strategy relies on using allogeneic cells to boost immune responses.
We develop an off the shelf cell and gene therapies derived from donors to promote stronger immune system responses to induce long-term or life-long cancer remission in some of the deadliest cancers.
Renovaro has grown from a single HIV treatment candidate to include two additional HIV candidates, an HBV pipeline, and expanded into cancer immunotherapies, specifically targeting challenging solid tumors like pancreatic cancer, which is now a primary focus.
Our Team
COMMITTED TO RADICALLY ACCELERATE PRECISION MEDICINE
Maurice van Tilburg – Glimne
Chairman & CEO RenovaroCube
Chairman Maurice van Tilburg has held several senior positions in the Financial Services industry and Tech enterprises combining general management, technology, operational service delivery, financial management, audit and product development. He is also an awarded artist that combines leadership roles in the industry with a successful series of art concepts. Mr. van Tilburg currently serves…
David Weinstein
Director & Chief Executive Officer (CEO)
Director & Chief Executive Officer (CEO) Mr. Weinstein has thirty years of experience with U.S. securities and investment banking firms. He has been a Managing Partner of Investment Banking since 2005. Prior to joining Renovaro Inc., Mr. Weinstein was Director of Dawson James Securitiesand, prior to that, Director of Research for National Securities Corporation and,…
Douglas W. Calder
Director
Director Since 2015, Mr. Calder has served as president and a director of Vycellix, Inc and its subsidiaries and affiliates. He has also served as a member of the board of directors for Zevra Therapeutics, Inc. (NASDAQ: ZVRA) since April 2023; member of the board of directors for NextGenNK since June 2019; member of the…
Mark Collins, Phd
Director
Director Dr. Collins has dedicated his 40-year career to leveraging computers in drug discovery, blending biology, AI, and software. He has played key roles in biotech startups, large Pharma, and tech companies, leading several to successful exits. Dr. Collins is currently the Chief Scientific Officer at UndauntedBio Inc., where he has served since 2022, a…
James A. McNulty
Director
Director Mr. McNulty serves as CFO for MIRALOGX, LLC, a privately held incubator which develops and licenses pharmaceutical intellectual property to private and public entities. Mr. McNulty is currently Interim CFO for Inhibitor Therapeutics, Inc. (OTCQB: INTI), where he has served since 2022. After leaving public accounting in 1998 after a 26-year career in Tampa…
Nathen Feuntes
Chief Financial Officer (CFO)
On January 2, 2025, the Company appointed Nathen Fuentes as Chief Financial Officer of the Company. Mr. Fuentes most recently served as Chief Financial Officer at Telomir Pharmaceuticals, an emerging leader in age-reversal science. Previously, Mr. Fuentes worked for mid-market private equity sponsored companies within the specialty healthcare industry, serving as Chief Financial Officer of…